Mantle cell lymphoma: A clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data

• Published in: Cancer reports 2022-07, Vol.5 (7), p.e1590-n/a
• Main Authors: Radhakrishnan, Vivek Sulekha, Lokireddy, Padmaja, Parihar, Mayur, Prakash, Prashanth Srirangapattana, Menon, Hari
• Format: Article
• Language: English
• Subjects: Abdomen; acalabrutinib; Adult; Antigens; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biopsy; Bone marrow; BTK inhibitors; Cell cycle; Flow cytometry; guidelines for mantle cell lymphoma; Humans; ibrutinib; Immunotherapy, Adoptive; India; India - epidemiology; Kinases; Lymphatic system; Lymphoma; Lymphoma, Mantle-Cell - drug therapy; Lymphoma, Mantle-Cell - therapy; mantle cell lymphoma; Medical prognosis; Morphology; Mutation; novel therapies; Pathophysiology; Review; small molecule inhibitors; targeted therapies; Tumors
• ISSN: 2573-8348; 2573-8348
• DOI: 10.1002/cnr2.1590

Background Mantle cell lymphoma (MCL) is a rare type of mature B‐cell lymphoid malignancy with the pathologic hallmark of translocation t(11;14) (q13, q32), which leads to an overexpression of Cyclin D1 (CCND1). The disease is also characterized by the presence of a high number of recurrent genetic alterations, which include aberrations in several cellular pathways. MCL is a heterogeneous disease with a wide range of clinical presentations and a majority presenting with aggressive disease in advanced stages. Recent findings Management of MCL is bereft with challenges due to its resistant and relapsing pattern. Despite improvements in remission durations, the disease is currently incurable with standard therapy and has a median survival of about 3–5 years. The use of small molecules like the bruton tyrosine kinase (BTK) and BCL2 inhibitors, for treating relapsed MCL has been established leading to a diminishing role for conventional chemotherapy. Combinations of small molecule inhibitors with or without chemoimmunotherapy, are showing promising results. Cellular therapy in the form of CAR‐T cell therapy, has been approved recently. Conclusions Personalized cancer treatment and chemo‐free regimens are showing promise and results from well‐planned long‐term studies are evolving. In India, there is a paucity of epidemiological, clinical, and research data in this field.